This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
Talk:Triple releasing agent: Difference between revisions
>Unity citation, grammatics |
>Unity Grammatics |
||
| Line 1: | Line 1: | ||
'''Triple releasing agent''' (also called a '''TRA''' or '''triple releaser''') is a informal term to describe a type of psychoactive substance which exerts its activity by inducing the release and increase in concentration of the three major central nervous [[monoamine]] neurotransmitters, [[serotonin]], [[norepinephrine]], and [[dopamine]] within the [[synapse]]s of various regions in the brain. In the field of neuropharmacology, they are more formally referred to as '''serotonin-norepinephrine-dopamine releasing agents (SNDRA)'''.{{citation needed}} | '''Triple releasing agent''' (also called a '''TRA''' or '''triple releaser''') is a informal term to describe a type of psychoactive substance which exerts its activity by inducing the release and increase in concentration of the three major central nervous [[monoamine]] neurotransmitters, [[serotonin]], [[norepinephrine]], and [[dopamine]] within the [[synapse]]s of various regions in the brain. In the field of neuropharmacology, they are more formally referred to as '''serotonin-norepinephrine-dopamine releasing agents (SNDRA)'''.{{citation needed}} | ||
In the context of [[psychonautics]] and [[recreational drug use]] triple releasing agents are typically associated with the ability to produce [[Euphoria|euphoriant]], [[entactogen]]ic, and [[stimulant|stimulating]] effects in a manner similar to [[MDMA]], [[MDA]], [[4-FA]] and other amphetamine-based compounds, with the entactogenic aspects being the most prominent. | In the context of [[psychonautics]] and [[recreational drug use]] triple releasing agents are typically associated with the ability to produce [[Euphoria|euphoriant]], [[entactogen]]ic, and [[stimulant|stimulating]] effects in a manner similar to [[MDMA]], [[MDA]], [[4-FA]] and other amphetamine-based compounds, with the serotonergic entactogenic aspects typically being the most prominent and desired effect. | ||
A closely related type of substance is a '''triple reuptake inhibitor (TRI)''', which also produces an increase in synaptic concentrations of the above-mentioned monoamines, albeit through a different mechanism. Relative to triple releasing agents, triple reuptake inhibitors have a long history been investigated for various potential medical uses<ref>Chen, Z., & Skolnick, P. (2007). Triple uptake inhibitors: therapeutic potential in depression and beyond. Expert Opinion on Investigational Drugs, 16(9), 1365-1377. http://dx.doi.org/10.1517/13543784.16.9.1365</ref> and FDA approval has been granted for the use of one such compound as an [[antidepressant]],{{citation needed}} and for the use of several others as [[Appetite suppression|anorectics]].{{citation needed}} | A closely related type of substance is a '''triple reuptake inhibitor (TRI)''', which also produces an increase in synaptic concentrations of the above-mentioned monoamines, albeit through a different mechanism. Relative to triple releasing agents, triple reuptake inhibitors have a long history been investigated for various potential medical uses<ref>Chen, Z., & Skolnick, P. (2007). Triple uptake inhibitors: therapeutic potential in depression and beyond. Expert Opinion on Investigational Drugs, 16(9), 1365-1377. http://dx.doi.org/10.1517/13543784.16.9.1365</ref> and FDA approval has been granted for the use of one such compound as an [[antidepressant]],{{citation needed}} and for the use of several others as [[Appetite suppression|anorectics]].{{citation needed}} | ||